Oct 22, 2018 Oncolytics Biotech® Announces Positive Clinical Trial Results for Pelareorep in Patients with KRAS Mutant Metastatic Colorectal Cancer for Presentation at ESMO 2018
Oct 11, 2018 Oncolytics Biotech® Announces Publication of Positive Clinical Results for Pelareorep in Abstract for ESMO 2018 Congress
Oct 2, 2018 Oncolytics Biotech® Announces a Publication Demonstrating That Intravenously Delivered Oncolytic Viruses Effectively Target Tumors Even in the Presence of Neutralizing Antibodies
Sep 28, 2018 Oncolytics Biotech® Enters into Common Stock Purchase Agreement for up to US$26 Million with Lincoln Park Capital, LLC
Sep 17, 2018 Oncolytics Biotech® Announces Investigator Sponsored Multiple Myeloma Study Combining REOLYSIN® and Nivolumab (Opdivo®) with Standard of Care
Sep 10, 2018 Oncolytics Biotech® Collaborates with SOLTI to Conduct a Window of Opportunity Study in Breast Cancer with Pelareorep
Sep 6, 2018 Oncolytics Biotech® Announces a Master Clinical Supply Agreement of an Anti-PD-L1 Checkpoint Inhibitor for use in the Company’s Clinical Program
